News Release

Association of fourth Pfizer-BioNTech vaccine dose with SARS-CoV-2 infection

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: Researchers found that 4-dose recipients of the Pfizer-BioNTech vaccine had a lower risk of acquiring COVID-19 than 3-dose recipients during the peak Omicron variant wave in this study of 29,000 health care workers in Israel.

Authors: Allon E. Moses, M.D., of the Hadassah-Hebrew University Medical Center in Jerusalem, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.